Related Experiment Videos
Viral hepatitis and liver transplantation
1Division of Gastroenterology, University of California San Francisco, USA. bzowej@itsa.ucsf.edu
Journal of Gastroenterology and Hepatology
|June 26, 1999
Summary
Hepatotropic viruses significantly impact transplant patient outcomes, causing disease and increasing mortality. New treatments combining antiviral and immunomodulatory agents are being developed for hepatitis B (HBV) and hepatitis C (HCV) infections.
Area of Science:
- Hepatology
- Transplant Medicine
- Infectious Diseases
Background:
- Hepatotropic viruses are significant pathogens in transplant recipients.
- These infections contribute to post-transplant morbidity and mortality.
- Current management strategies for viral hepatitis in transplant patients are evolving.
Purpose of the Study:
- To highlight the importance of hepatotropic viruses in transplantation.
- To discuss the approach to treating these viral infections post-transplant.
- To identify areas needing further research in pathogenesis and long-term outcomes.
Main Methods:
- Review of current literature on hepatotropic viruses in transplantation.
- Analysis of the impact of viral hepatitis on transplant patient outcomes.
- Discussion of emerging treatment strategies.
Main Results:
- Hepatotropic viruses pose a considerable risk in transplant patients.
- Significant unanswered questions remain regarding long-term disease natural history.
- Understanding of infection pathogenesis in transplant settings is still developing.
Conclusions:
- Further investigation is crucial for a complete understanding of viral pathogenesis in transplant patients.
- New therapeutic approaches are focusing on combination therapies.
- Antiviral and immunomodulatory agents are key in developing future treatments for HBV and HCV.